Metraipolis › archive › dc_5407bc3ea67c
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab — Europe PMC PMID:41199847
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41199847
- DOI
- 10.3389/fonc.2025.1681420
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T04:04:31.975Z
- SHA-256 of the archived text
8e57905384a5a2cefe95c88b64143ea2e9ac3e10e3530916f370f2fffa9bbe92- Stable URL of this page
https://metraipolis.com/documento/dc_5407bc3ea67c
How to cite
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab — Europe PMC PMID:41199847 — Europe PMC (en), https://europepmc.org/article/MED/41199847 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5407bc3ea67c (Metraipolis archive dc_5407bc3ea67c, sha256 8e57905384a5a2cefe95c88b64143ea2e9ac3e10e3530916f370f2fffa9bbe92)
BibTeX
@misc{dc5407bc3ea67c,
title = {Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab — Europe PMC PMID:41199847},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41199847},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5407bc3ea67c; sha256 8e57905384a5a2cefe95c88b64143ea2e9ac3e10e3530916f370f2fffa9bbe92},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41199847. Agents can read the archived copy with the MCP tool read_document.